HYBIO(SZ:300199)2025-01-17 11:35Financial Performance - The company expects a net profit loss of between 140 million and 190 million CNY for 2024, compared to a loss of 513.88 million CNY in the same period last year[3] - The net profit loss after deducting non-recurring gains and losses is projected to be between 200 million and 250 million CNY, compared to a loss of 590.91 million CNY in the previous year[3] Revenue Growth - The significant reduction in net loss is attributed to continuous growth in overseas business, particularly in peptide formulations and raw materials, which is expected to drive overall revenue growth[5] - The change in revenue structure has led to an increase in operating profit margins, as the overseas business, which has a higher profit margin, has seen substantial growth compared to the lower-margin domestic business[6] Operational Efficiency - The company has improved operational efficiency, resulting in a reduction in expense ratios[6]